(VIANEWS) – Shares of POXEL (CAC 40: POXEL.PA) fell by a staggering 15.47% in 5 sessions from €0.77 to €0.65 at 14:05 EST on Tuesday, after four successive sessions in a row of losses. CAC 40 is sliding 0.87% to €7,413.24, following the last session’s downward trend.
POXEL’s last close was €0.66, 76.48% under its 52-week high of €2.82.
About POXEL
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, POXEL has a trailing twelve months EPS of €-1.09.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -323.36%.
Moving Average
POXEL’s worth is under its 50-day moving average of €0.70 and way below its 200-day moving average of €1.23.
Volume
Today’s last reported volume for POXEL is 51856 which is 68.76% below its average volume of 155900.
Revenue Growth
Year-on-year quarterly revenue growth declined by 99.4%, now sitting on 206k for the twelve trailing months.
More news about POXEL (POXEL.PA).
